Similar articles

• Safety and Efficacy of Mitapivat in Pyruvate Kinase Deficiency.

  Grace RF, Rose C, Layton DM, Galactéros F, Barcellini W, Morton DH, van Beers EJ, Yaish H, Ravindranath Y, Kuo KHM, Sheth S, Kwiatkowski JL, Barbier AJ, Bodie S, Silver B, Hua L, Kung C, Hawkins P, Jouvin MH, Bowden C, Glader B. Grace RF, et al. N Engl J Med. 2019 Sep 5;381(10):933-944. doi: 10.1056/NEJMoa1902678. N Engl J Med. 2019. PMID: 31483964 Clinical Trial.
• Bone mineral density in adult patients with pyruvate kinase deficiency on long-term mitapivat treatment.

  Al-Samkari H, Grace RF, Glenthøj A, Andres O, Barcellini W, Galacteros F, Kuo KHM, Layton DM, Morado M, Viprakasit V, Tai F, Urbstonaitis R, Morales J, McGee B, Beers EJV. Al-Samkari H, et al. Haematologica. 2024 Mar 1;109(3):963-967. doi: 10.3324/haematol.2023.282884. Haematologica. 2024. PMID: 37731369 Free PMC article. No abstract available.
• Mitapivat versus Placebo for Pyruvate Kinase Deficiency.

  Shah AJ, Schwartz JD, Segovia JC. Shah AJ, et al. N Engl J Med. 2022 Jun 30;386(26):2538-2539. doi: 10.1056/NEJMc2206275. N Engl J Med. 2022. PMID: 35767453 No abstract available.
• Updates and advances in pyruvate kinase deficiency.

  Luke N, Hillier K, Al-Samkari H, Grace RF. Luke N, et al. Trends Mol Med. 2023 May;29(5):406-418. doi: 10.1016/j.molmed.2023.02.005. Epub 2023 Mar 17. Trends Mol Med. 2023. PMID: 36935283 Free PMC article. Review.
• Who should be eligible for gene therapy clinical trials in red blood cell pyruvate kinase deficiency (PKD)?: Toward an expanded definition of severe PKD.

  Schwartz JD, Barcellini W, Grace RF, Bianchi P, Zanella A, López Lorenzo JL, Sevilla J, Shah AJ, Glader B, Nicoletti E, Navarro Ordoñez S, Segovia JC. Schwartz JD, et al. Am J Hematol. 2022 Mar 1;97(3):E120-E125. doi: 10.1002/ajh.26458. Epub 2022 Jan 24. Am J Hematol. 2022. PMID: 34989415 Free PMC article. Review. No abstract available.